Security
Vanc Pharmaceuticals, Inc. Ordinary Shares · NUVPD
NUVPDOTCCommon stockHistorical · closed Dec 28, 2016CIK 1355736Updated Nov 17, 2026
Name history
Vanc Pharmaceuticals Inc. · through Oct 5, 2018NUVA Pharmaceuticals Inc. · through Jun 17, 2014ALDA Pharmaceuticals Corp. · through Oct 29, 2013
Current securities for this SEC filerAVCRF · OTCAVCR · TSXV
NUVPD price & chart
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2024 · CADSource
cash flow · annual statements
| Line item | Q4 2023 | Q4 2022 | Q3 2023 | Q3 2022 | Q2 2023 | Q2 2022 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Profit or LossCAD | — | — | -285,062Source | -180,398Source | -284,225Source | -207,363Source | -668,977Source | -701,215Source | -818,228Source | -1,708,132Source |
| Additional Financial Items | ||||||||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableCAD | — | — | — | — | — | — | 8,102Source | 338,090Source | -687,492Source | 79,620Source |
| AdjustmentsForFinanceCostsCAD | — | — | — | — | — | — | — | — | — | 38,438Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableCAD | — | — | — | — | — | — | -158,401Source | 176,325Source | 268,416Source | -69,592Source |
| AdjustmentsForSharebasedPaymentsCAD | — | — | — | — | — | — | 541,164Source | 703,612Source | 331,522Source | 495,791Source |
| GeneralAndAdministrativeExpenseCAD | — | — | 79,720Source | 84,434Source | 101,780Source | 73,032Source | 409,398Source | 339,369Source | 250,144Source | 183,000Source |
| ProceedsFromIssuingSharesCAD | — | — | — | — | — | — | — | — | — | 2,404,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesCAD | — | — | — | — | — | — | 24,253Source | 25,288Source | 5,171Source | 35,006Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesCAD | — | — | — | — | — | — | — | — | — | 1,000,000Source |
income statement · annual statements
| Line item | Q4 2023 | Q4 2022 | Q3 2023 | Q3 2022 | Q2 2023 | Q2 2022 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Total Revenue | — | — | — | — | — | — | — | — | — | — |
| Additional Financial Items | ||||||||||
| ApplicableTaxRatenumber | — | — | — | — | — | — | — | — | 0.27Source | 0.27Source |
| BasicEarningsLossPerShareCAD/shares | — | — | 0Source | 0Source | 0Source | 0Source | -0.01Source | -0.01Source | -0.01Source | -0.02Source |
| DepreciationAndAmortisationExpenseCAD | — | — | 667Source | 75,373Source | 781Source | 22,065Source | 3,137Source | 2,347Source | 631Source | 17,984Source |
| DilutedEarningsLossPerShareCAD/shares | — | — | 0Source | 0Source | 0Source | 0Source | -0.01Source | -0.01Source | — | — |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesCAD | — | — | 304,328Source | 58,354Source | 168,518Source | 9,069Source | 541,164Source | 703,612Source | 331,522Source | 495,791Source |
| FinanceCostsCAD | — | — | — | — | — | — | — | — | — | 38,438Source |
| GeneralAndAdministrativeExpenseCAD | — | — | 79,720Source | 84,434Source | 101,780Source | 73,032Source | 409,398Source | 339,369Source | 250,144Source | 183,000Source |
| GrossProfitCAD | — | — | 261,778Source | 215,961Source | 229,471Source | 56,874Source | 1,880,287Source | 1,203,396Source | 456,793Source | 30,521Source |
| InterestExpenseCAD | — | — | — | — | — | — | — | — | — | 21,096Source |
| ProfessionalFeesExpenseCAD | — | — | 37,808Source | 33,440Source | 92,766Source | 52,514Source | 255,655Source | 285,935Source | 150,585Source | 189,796Source |
| ProfitLossBeforeTaxCAD | — | — | — | — | — | — | 129,001Source | -693,253Source | — | — |
| RevenueFromInterestCAD | — | — | — | — | 111Source | 2,502Source | 1,235Source | 3,284Source | 8,086Source | 581Source |
| Total Revenue | — | — | —Source | —Source | — | — | — | — | — | — |